For now, there’s no hard and fast rule when it comes to the slippery slope CBD companies will have to contend with until the FDA starts approving products. Until then, it’s best to err on the side of caution and avoid making any claims you can’t back up with hard science and cited studies, lest draw the ire of government officials who can and will put you out of business if you don’t heed their warnings.
New aggregated polls reveal that 55% of respondents believe marijuana is not dangerous, and a…
Every Croptober, growers waste time on folklore instead of physics. We break down the science…
Leafly's 2026 cannabis voter guide for the midterms is the only plan you need to…
Come along on an Emerald Triangle road trip with Lindsay MaHarry to see some of…
This month an Iowa church got what every sacramental-plant congregation dreams about: a path to…
The cannabis industry does not need another study, another tax revenue report, or another state-level…